Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

October 12, 2017: By Jon Swedien

1 Ophthalmic NewsAzura Ophthalmics has completed a $16 million Series B funding round that will enable it to further develop its dry eye disease treatment candidates, the Israeli company announced Oct. 10.

Azura is developing a portfolio of compounds in combination with a novel drug delivery platform designed to treat meibomian gland dysfunction (MGD), the leading cause of dry eye disease, the company said.

The firm also is preparing for a Phase IIa trial of a drug therapy that has shown efficacy in an initial clinical proof of concept study.

The round was led by a syndicate of OrbiMed, TPG Biotech, and Brandon Capital’s Medical Research Commercialisation Fund, with participation from an existing investor, Ganot Capital.

The company also announced Oct. 10 that Anat Naschitz of OrbiMed, Heather Preston of TPG Biotech, and Chris Nave of Brandon Capital will join the company’s board of directors.

The board also includes Guy Katsav of Ganot Capital, Azura CEO Marc Gleeson, and Yair Alster, MD, Azura’s founder and chief technology officer.

Alster previously co-founded several companies, including Forsight Vision 4 (sold to Roche-Genentech), Forsight Vision 5 (sold to Allergan), and Notal Vision, a commercial stage company.

Gleeson spent 14 years at Allergan as vice president of global marketing for ophthalmology, and then he joined Oculeve.

Azura has also named Charles Bosworth, formerly of Allergan, as its chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022